Innovation Pharmaceuticals Poised to Reuse Agent for COVID-19 Vaccine
Innovation Pharmaceuticals is investigating an FDA approved agent as a COVID-19 Vaccine.
The vaccine candidate, Brilacidin, is a potential novel coronavirus (COVID-19) treatment, one of the few promising drugs targeting COVID-19 that has been tested in FDA clinical trials for other indications, potentially enabling its expedited use against COVID-19.
Brilacidin is an immunomodulatory agent with anti-inflammatory/antibiotic properties. It is Innovation's lead drug candidate in its defensin-mimetic franchise.
The Company also has successfully completed a Phase 2 trial of Brilacidin in Oral Mucositis, aligning with the FDA on a planned Phase 3 program.
On the virus treatment front, doctors are agonizing over the possibility they may have to ration the use of remdesivir, that experimental drug that could be used to treat Covid-19 patients. Meanwhile, another study has found hydroxychloroquine, the drug touted by some politicians as a potential treatment, is not effective against the disease.